CERS

CERUS CORP (CERS) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction in platelets, plasma, and red blood cells. The company operates in one reportable segment and relies on product sales and government contracts (BARDA, DoD, FDA) for revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 13% year-over-year, driven by a 13% increase in product revenue (primarily U.S. disposable platelet kit sales) and a 12% increase in government contract revenue (driven by the new 2024 BARDA Agreement).
• Margin Expansion: Gross margin on product sales improved to 59% from 55% in the prior year, attributed to the capitalization of inventoriable charges and the release of favorable variances.
• Expense Increases: R&D expenses rose 15% to $16.6 million due to costs for a new LED-based illuminator and increased compensation. SG&A expenses increased 2% to $20.3 million, also driven by compensation costs.
• Cash Flow: Net cash used in operating activities was $0.8 million, a reversal from the $2.0 million provided in Q1 2024, primarily due to increased inventory purchases and timing of collections.
• Inventory Build: Total inventories increased to $63.3 million from $52.3 million, with current inventories rising to $48.2 million.

Outlook, Risks, and Management Commentary

• Red Blood Cell (RBC) System: The company's MDR application for the RBC system in the EU was closed in October 2024 due to insufficient data on the impurity profile. A revised application has been submitted to a new Competent Authority. The company anticipates delays in the U.S. RedeS clinical trial enrollment, potentially pushing the final PMA module submission beyond the previously anticipated second half of 2026.
• Government Funding: The company holds two BARDA agreements (2016 and 2024) with potential funding opportunities totaling over $450 million. However, funding is contingent on meeting milestones and government budget availability. The 2016 agreement expires in September 2026.
• Debt Obligations: The Term Loan Credit Agreement ($65 million principal) is interest-only until April 2026. Unless restructured or extended, principal amortization begins April 1, 2026. The interest rate is approximately 11.3%.
• Supply Chain & Tariffs: The company faces risks from potential new tariffs (including a 10% baseline global tariff and 125% on China goods mentioned in risk factors) and supply chain disruptions. Reliance on sole suppliers (e.g., Fresenius) remains a critical risk.
• Liquidity: Management believes cash, investments, and government contract reimbursements are sufficient to meet capital requirements for at least the next 12 months.

Investor Verification Checklist

• RBC Regulatory Status: Verify the timeline and requirements for the resubmitted EU MDR application and the impact of RedeS trial delays on U.S. FDA approval.
• BARDA Funding Certainty: Assess the risk of government funding cuts or failure to meet milestones under the 2016 and 2024 BARDA agreements.
• Debt Amortization: Confirm the company's strategy for the Term Loan principal payments commencing April 2026 and the impact on working capital.
• Inventory Valuation: Review the $63.3 million inventory balance for potential obsolescence risks, given the 18-24 month shelf life of disposable kits.
• Tariff Impact: Evaluate the potential financial impact of new U.S. tariffs on imported components and raw materials.